Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’ Brien, Suman Rao, Katsuyuki Hotta, Kristel Vandormael, Antonio Riccio, Jing Yang, M. Catherine Pietanza, Julie R. Brahmer

Journal of Clinical Oncology, 2019

LungenClinic Grosshansdorf, Universidad de Las Palmas de Gran Canaria, Hospital Universitario Insular de Gran Canaria, Kingston General Hospital, The University of Sydney, Westmead Hospital, Országos Korányi Tbc és Pulmonológiai Intézet, Meir Medical Center, Soroka Medical Center, University of Wollongong, Cancer Trials Ireland, St. James's Hospital, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, MedStar Franklin Square Medical Center, Okayama University Hospital, MSD (Belgium), Merck & Co., Inc., Rahway, NJ, USA (United States), Sidney Kimmel Comprehensive Cancer Center

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with Journal of Clinical Oncology. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1685

Citations

View on Google Scholar

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Abstract

Journal Details

Join JournalsHub

Welcome Back